• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Absci Corporation (Amendment)

    3/20/23 4:22:21 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email
    SC 13D/A 1 d10603587_13d-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 3)*

     

     

    Absci Corporation
    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value
    (Title of Class of Securities)

     

     

    00091E109
    (CUSIP Number)

     

     

    Eli Casdin

    Casdin Capital, LLC

    1350 Avenue of the Americas, Suite 2600

    New York, New York

    Telephone Number (212) 897-5438

    (Name, Address and Telephone Number of Person Authorized to Receive

    Notices and Communications)

     

     

    March 16, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [  ].

     

    _______________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     


    CUSIP No.
    00091E109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Capital, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
        (a)   [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      5,533,260  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      5,533,260  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      5,533,260  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      6.0%  

     

    14. TYPE OF REPORTING PERSON  
         
      IA  

     

     


    CUSIP No.
    00091E109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Partners Master Fund, L.P.  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
        (a)   [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      4,560,000  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      4,560,000  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      4,560,000  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      4.9%  

     

    14. TYPE OF REPORTING PERSON  
         
      PN  

     

     


    CUSIP No.
    00091E109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Partners GP, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
        (a)   [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      4,560,000  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      4,560,000  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      4,560,000  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      4.9%  

     

    14. TYPE OF REPORTING PERSON  
         
      OO  

     

     


    CUSIP No.
    00091E109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Eli Casdin  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
        (a)   [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      5,533,260  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      5,533,260  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      5,533,260  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      6.0%  

     

    14. TYPE OF REPORTING PERSON  
         
      IN  

     

     

     

    CUSIP No. 00091E109    

     

    Item 1. Security and Issuer.  

     

      The name of the issuer is Absci Corporation, a Delaware corporation (the "Issuer").  The address of the Issuer's principal executive offices is 18105 SE Mill Plain Blvd, Vancouver, Washington, 98683.  This Schedule 13D relates to the Issuer's Common Stock, $0.0001 par value (the "Shares").  
         
         

     

    Item 2. Identity and Background.  

     

      (a), (f) This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company (“Casdin”), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the “Fund”), Casdin Partners GP, LLC, a Delaware limited liability company (the “GP”) and Eli Casdin, a United States citizen (collectively, the "Reporting Persons").    
           
      (b) The principal business address for each of the Reporting Persons is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019.  
           
      (c) Eli Casdin is the managing member of Casdin and the GP.  The principal business of Casdin is serving as an investment adviser to its clients.  The principal business of the GP is serving as the general partner to certain private funds.  Casdin is the investment manager to the Fund and the GP is the general partner of the Fund.  The principal business of the Fund is purchasing, holding and selling securities for investment purposes.  
           
      (d), (e) During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.  The Reporting Persons disclaim membership in a group.    
         

     

     

     

    Item 3. Source and Amount of Funds or Other Consideration.  
         
      The funds for the purchase of the Shares came from the working capital of private investment funds managed by Casdin, including the Fund, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion.  No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.      
         

     

    Item 4. Purpose of Transaction.  
         
     

    The Reporting Persons have acquired their Shares of the Issuer for investment. The Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate transaction involving the Issuer; (b) any change in the present Board of Directors or management of the Issuer; (c) any material change in the present capitalization or dividend policy of the Issuer; (d) any material change in the operating policies or corporate structure of the Issuer; (e) any change in the Issuer's charter or by-laws; (f) the Shares of the Issuer ceasing to be listed from a national securities exchange or to ceasing to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; or (g) causing the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934.

     

    On July 8, 2022, Eli Casdin, a director of the Issuer, notified the Issuer of his decision to step down from the Board of Directors of the Issuer, effective July 11, 2022. Mr. Casdin’s decision was not the result of any disagreement with the Issuer on matters related to the Issuer’s operations, policies or practices.

     

    The Reporting Persons, however, reserve the right, at a later date, to effect one or more of such changes and may dispose of or enter into other transactions in the shares they may be deemed to beneficially own.

     

    The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value.

     

    The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should it determine to do so, and/or to recommend courses of action to management and the shareholders of the Issuer.

     
         

     

     

     

    Item 5. Interest in Securities of the Issuer.  
         
      (a) - (e)

    As of the date hereof, Casdin and Eli Casdin may be deemed to be the beneficial owners of 5,533,260 Shares, constituting 6.0% of the Shares, based upon 92,394,909* Shares outstanding.

     

    Casdin and Eli Casdin have the sole power to vote or direct the vote of 0 Shares; have the shared power to vote or direct the vote of 5,533,260 Shares; have the sole power to dispose or direct the disposition of 0 Shares; and have the shared power to dispose or direct the disposition of 5,533,260 Shares.

     

    As of the date hereof, the Fund and the GP may be deemed to be the beneficial owners of 4,560,000 Shares, constituting 4.9% of the Shares, based upon 92,394,909* Shares outstanding.

     

    The Fund and the GP have the sole power to vote or direct the vote of 0 Shares; have the shared power to vote or direct the vote of 4,560,000 Shares; have the sole power to dispose or direct the disposition of 0 Shares; and have the shared power to dispose or direct the disposition of 4,560,000 Shares.

     

    The transactions by the Reporting Persons in the Shares during the past sixty days are set forth in Exhibit B. All such transactions were carried out in open market transactions.

     

    All of the Shares are beneficially owned by the Fund and another private investment fund managed by Casdin.

     

    The Fund and the GP no longer own more than 5% of the total outstanding Shares. Consequently, this is the final amendment to the Schedule 13D and constitutes an “exit filing” for the Fund and the GP.

     

    *This outstanding Shares figure reflects the number of outstanding Shares as reported in the 10-Q filed by the Issuer on November 9, 2022.

     
           

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.  
         
      Not Applicable  
         

     

    Item 7. Material to be Filed as Exhibits.  

     

     

    Exhibit A: Joint Filing Agreement

         

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      March 20, 2023
      (Date)
       
       
      Casdin Capital, LLC*
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      Casdin Partners Master Fund, L.P.
      By: Casdin Partners GP, LLC, its general partner
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      Casdin Partners GP, LLC*
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin*
      Eli Casdin

     

    * This reporting person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 10001).

     

     

    Exhibit A

     

     

    AGREEMENT

     

    The undersigned agree that this Schedule 13D amendment, dated March 20, 2023, relating to the Common Stock, $0.0001 par value of Absci Corporation shall be filed on behalf of the undersigned.

     

      March 20, 2023
      (Date)
       
       
      Casdin Capital, LLC
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      Casdin Partners Master Fund, L.P.
      By: Casdin Partners GP, LLC, its general partner
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      Casdin Partners GP, LLC
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin
      Eli Casdin

     

     

     

    Exhibit B

     

     

    Schedule of Transactions in Shares

     

     

    Date of Transaction Title of Class Number of Shares Acquired Number of Shares Disposed

    Price Per Share

             
    2/13/2023 Common Stock, $0.0001 par value   40,000 $2.6330
    2/14/2023 Common Stock, $0.0001 par value   55,000 $2.6656
    2/14/2023 Common Stock, $0.0001 par value   5,000 $2.6278
    2/15/2023 Common Stock, $0.0001 par value   25,000 $2.7269
    2/15/2023 Common Stock, $0.0001 par value   5,000 $2.7419
    2/16/2023 Common Stock, $0.0001 par value   40,000 $2.7032
    2/17/2023 Common Stock, $0.0001 par value   25,000 $2.6436
    2/21/2023 Common Stock, $0.0001 par value   25,000 $2.4634
    2/21/2023 Common Stock, $0.0001 par value   45,000 $2.3946
    2/22/2023 Common Stock, $0.0001 par value   100,000 $2.4315
    2/23/2023 Common Stock, $0.0001 par value   50,000 $2.3463
    2/23/2023 Common Stock, $0.0001 par value   5,000 $2.3200
    2/24/2023 Common Stock, $0.0001 par value   20,000 $2.2066
    2/24/2023 Common Stock, $0.0001 par value   9,881 $2.2251
    2/27/2023 Common Stock, $0.0001 par value   5,000 $2.1946
    2/28/2023 Common Stock, $0.0001 par value   30,119 $2.1281
    3/1/2023 Common Stock, $0.0001 par value   20,000 $2.0120
    3/2/2023 Common Stock, $0.0001 par value   155,000 $2.1279
    3/2/2023 Common Stock, $0.0001 par value   35,000 $2.1781
    3/2/2023 Common Stock, $0.0001 par value   10,000 $2.1481
    3/3/2023 Common Stock, $0.0001 par value   30,000 $2.1759
    3/6/2023 Common Stock, $0.0001 par value   17,000 $2.1638
    3/6/2023 Common Stock, $0.0001 par value   3,000 $2.1915
    3/6/2023 Common Stock, $0.0001 par value   5,000 $2.0740
    3/7/2023 Common Stock, $0.0001 par value   48,500 $2.1427
    3/7/2023 Common Stock, $0.0001 par value   1,500 $2.1377
    3/8/2023 Common Stock, $0.0001 par value   30,000 $2.0350
    3/8/2023 Common Stock, $0.0001 par value   25,000 $1.9839
    3/10/2023 Common Stock, $0.0001 par value   15,000 $1.9345
    3/13/2023 Common Stock, $0.0001 par value   10,000 $1.7845
    3/14/2023 Common Stock, $0.0001 par value   15,000 $1.7676
    3/15/2023 Common Stock, $0.0001 par value   15,000 $1.7151
    3/16/2023 Common Stock, $0.0001 par value   10,000 $1.6822
    3/17/2023 Common Stock, $0.0001 par value   10,000 $1.5882

     

     

    Get the next $ABSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    3/14/2024$13.00Sector Outperform
    Scotiabank
    12/5/2023$3.00Overweight
    KeyBanc Capital Markets
    5/4/2023$4.00Buy
    H.C. Wainwright
    8/12/2022Overweight → Underweight
    JP Morgan
    7/18/2022$8.00Buy
    Truist
    More analyst ratings

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Redmile Group, Llc bought $999,999 worth of shares (222,222 units at $4.50) (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/5/24 9:30:43 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Absci Corporation with a new price target

      Needham initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00

      1/22/25 7:30:02 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Guggenheim initiated coverage on Absci Corporation with a new price target

      Guggenheim initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $10.00

      10/2/24 7:13:36 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Morgan Stanley initiated coverage on Absci Corporation with a new price target

      Morgan Stanley initiated coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00

      7/3/24 7:24:12 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

      VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

      4/14/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci to Participate in Upcoming Investor Conferences

      VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceFireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time 24th Annual Needham Virtual Healthcare ConferenceFireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time Interested parties may access live and archived webcasts of the fireside chat sessions on the company's

      3/26/25 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

      Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full

      3/18/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Absci Corporation

      SC 13G - Absci Corp (0001672688) (Subject)

      11/14/24 4:02:50 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Absci Corporation

      SC 13G/A - Absci Corp (0001672688) (Subject)

      11/12/24 9:50:12 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Absci Corporation (Amendment)

      SC 13D/A - Absci Corp (0001672688) (Subject)

      3/5/24 5:15:30 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Financials

    Live finance-specific insights

    See more
    • Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

      VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

      4/14/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

      Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full

      3/18/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

      VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available fo

      3/4/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

      Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.  In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e

      1/10/24 7:30:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

      VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success. During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a

      6/6/23 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Welcomes Meta Senior Executive to Board of Directors

      VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a generative AI drug creation company, today announced Meta Connectivity VP Dan Rabinovitsj as the newest member of its Board of Directors. With three decades of leadership in scaling technologies, innovating business models and growing companies, Mr. Rabinovitsj will provide strategic insights as Absci continues to scale its unprecedented combination of AI and wet lab capabilities to help create better biologics for patients, faster. "Absci has impressed me with their technology and data, together which have the potential to turn Absci's bold vision into reality: to create therapeutics at a

      11/2/22 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Walker Shelby J. was granted 59,300 shares (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:43:06 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SVP, CAO Bedrick Todd was granted 29,700 shares, increasing direct ownership by 22% to 167,827 units (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:42:16 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Chief Executive Officer Mcclain Sean was granted 190,200 shares, increasing direct ownership by 2% to 8,384,621 units (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:41:15 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Absci Corporation

      SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)

      5/12/25 10:24:40 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Absci Corporation

      SCHEDULE 13D/A - Absci Corp (0001672688) (Subject)

      4/29/25 9:31:04 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by Absci Corporation

      DEFA14A - Absci Corp (0001672688) (Filer)

      4/28/25 4:13:02 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care